PMID- 15328528
OWN - NLM
STAT- MEDLINE
DCOM- 20050214
LR  - 20150311
IS  - 0893-133X (Print)
IS  - 0893-133X (Linking)
VI  - 29
IP  - 12
DP  - 2004 Dec
TI  - Neurotensin receptor antagonist SR 142948A alters Fos expression and 
      extrapyramidal side effect profile of typical and atypical antipsychotic drugs.
PG  - 2200-7
AB  - Antipsychotic drugs (APDs) have previously been shown to alter Fos expression in 
      a regionally specific manner. Increases in Fos expression in the nucleus 
      accumbens (NAcc) are common to all clinically effective APDs. In contrast, 
      APD-induced Fos expression increases in the caudate-putamen (CPu) and prefrontal 
      cortex (PFC) are associated with the extrapyramidal side effect liability of 
      typical APDs or the effectiveness against negative symptoms of atypical APDs, 
      respectively. Considerable evidence suggests that the neuropeptide neurotensin 
      (NT) mediates some of the effects of APDs. To determine whether NT 
      neurotransmission is also involved in APD-induced Fos expression in brain regions 
      relevant for therapeutic efficacy, the NT receptor antagonist SR 142948A (10 or 
      100 microg/kg i.p.) was coadministered with APDs (haloperidol (2.0 mg/kg s.c.), 
      olanzapine (5 mg/kg i.p.), or clozapine (20 mg/kg s.c.)). Fos expression was 
      evaluated in the PFC, NAcc shell, dorsomedial, and dorsolateral CPu and the 
      lateral septum. SR 142948A attenuated haloperidol-induced Fos expression in the 
      CPu but, in contrast, increased olanzapine-induced Fos expression in this brain 
      region. The effects of the NT receptor antagonist were paralleled by its effects 
      on catalepsy in olanzapine--but not haloperidol--treated animals.
FAU - Binder, Elisabeth B
AU  - Binder EB
AD  - Laboratory of Neuropsychopharmacology, Department of Psychiatry and Behavioral 
      Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA.
FAU - Kinkead, Becky
AU  - Kinkead B
FAU - Owens, Michael J
AU  - Owens MJ
FAU - Nemeroff, Charles B
AU  - Nemeroff CB
LA  - eng
GR  - MH-39415/MH/NIMH NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Neuropsychopharmacology
JT  - Neuropsychopharmacology : official publication of the American College of 
      Neuropsychopharmacology
JID - 8904907
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Imidazoles)
RN  - 0 (Oncogene Proteins v-fos)
RN  - 0 (Receptors, Neurotensin)
RN  - 0 (SR 142948A)
RN  - PJY633525U (Adamantane)
SB  - IM
MH  - Adamantane/*analogs & derivatives/*pharmacology
MH  - Analysis of Variance
MH  - Animals
MH  - Antipsychotic Agents/*pharmacology
MH  - Behavior, Animal
MH  - Catalepsy/chemically induced/physiopathology
MH  - Cell Count/methods
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Imidazoles/*pharmacology
MH  - Immunohistochemistry/methods
MH  - Male
MH  - Neostriatum/anatomy & histology/*drug effects/metabolism
MH  - Oncogene Proteins v-fos/*metabolism
MH  - Prefrontal Cortex/anatomy & histology/*drug effects
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Neurotensin/antagonists & inhibitors
MH  - Time Factors
EDAT- 2004/08/26 05:00
MHDA- 2005/02/16 09:00
CRDT- 2004/08/26 05:00
PHST- 2004/08/26 05:00 [pubmed]
PHST- 2005/02/16 09:00 [medline]
PHST- 2004/08/26 05:00 [entrez]
AID - 1300546 [pii]
AID - 10.1038/sj.npp.1300546 [doi]
PST - ppublish
SO  - Neuropsychopharmacology. 2004 Dec;29(12):2200-7. doi: 10.1038/sj.npp.1300546.